No Yes Ok

Archive

« Older Entries Newer Entries »

Rudy Dekeyser and Clemens van Blitterswijk join LSP Thursday, March 1st, 2012
[ NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA ] Amsterdam, February 29, 2012 – Life Sciences Partners (LSP), the European health care investment group, today announces the addition of Rudy Dekeyser and Clem [...]
arGEN-X enters into a therapeutic antibody alliance with Shire Wednesday, February 29th, 2012
HUMAN ANTIBODY PRODUCT COLLABORATION IN RARE DISEASES Rotterdam, the Netherlands and Ghent, Belgium February 29, 2012 – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclon [...]
BioCapital Europe - Presenting companies announced Tuesday, February 28th, 2012
BioCapital Europe, Europe's premier life sciences investment conference organised by LSP (Life Sciences Partners) and ABN AMRO, is delighted to announce the presenting companies for its 10th consecutive event on [...]
Curetis AG Initiates Prospective Clinical Trial for Rapid Pneumonia Diagnostics Thursday, February 16th, 2012
Expected CE-marking and launch in Europe in 2012 Holzgerlingen, Germany, February 16, 2012 -- Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagn [...]
Achmea en LSP lanceren het LSP-Health Economics Fund voor innovatie in de zorg Friday, February 10th, 2012
Zeist / Amsterdam, 10 februari 2012 – Verzekeraar Achmea en investeringsmaatschappij Life Sciences Partners (LSP) hebben de voorbereidingen afgerond voor de inrichting van een investeringsfonds voor innovaties in de zo [...]
arGEN-X advances a third therapeutic antibody program into preclinical development Wednesday, February 8th, 2012
ARGX-111 IS AN ANTI-C-MET ANTIBODY WITH BROAD APPLICABILITY IN CANCER Rotterdam, the Netherlands and Ghent, Belgium February 8, 2012–arGEN-X, a biopharmaceutical company focused on the discovery and development of h [...]
Hybrigenics revenues grew 45% to EUR 6.6 million in 2011 Monday, January 30th, 2012
Hybrigenics Services contributed for EUR 4.1 million, a 17% growth In 2011, Hybrigenics Pharma has signed a major drug discovery contract and expanded the clinical development scope of inecalcitol Paris, 30 January [...]
Prosensa Raises €23 Million in New Equity Financing Led by New Enterprise Associates Wednesday, January 25th, 2012
Leiden, The Netherlands, 25 January 2012 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet needs, announced today that it has raised €23 million [...]
Pronota announces EUR 3.7 million Series C financing; management and board changes Friday, January 20th, 2012
Ghent, Belgium; Pronota NV today announced the close of a Series C financing, raising EUR 3.7 million from existing investors; LSP, Gimv, Biotech Fund Flanders, KBC Private Equity, Johnson & Johnson Development Corporati [...]
Hybrigenics targets chronic lymphocytic leukemia (CLL) as the third therapeutic indication for its oral inecalcitol Thursday, January 19th, 2012
Hybrigenics filed a clinical trial application to test inecalcitol, a vitamin D receptor agonist, in CLL patients Hybrigenics started a collaboration with Necker Institute, Paris,on vitamin D receptor and CLL Paris [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

« Older Entries Newer Entries »

Rudy Dekeyser and Clemens van Blitterswijk join LSP Thursday, March 1st, 2012
[ NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA ] Amsterdam, February 29, 2012 – Life Sciences Partners (LSP), the European health care investment group, today announces the addition of Rudy Dekeyser and Clem [...]
arGEN-X enters into a therapeutic antibody alliance with Shire Wednesday, February 29th, 2012
HUMAN ANTIBODY PRODUCT COLLABORATION IN RARE DISEASES Rotterdam, the Netherlands and Ghent, Belgium February 29, 2012 – arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclon [...]
BioCapital Europe - Presenting companies announced Tuesday, February 28th, 2012
BioCapital Europe, Europe's premier life sciences investment conference organised by LSP (Life Sciences Partners) and ABN AMRO, is delighted to announce the presenting companies for its 10th consecutive event on [...]
Curetis AG Initiates Prospective Clinical Trial for Rapid Pneumonia Diagnostics Thursday, February 16th, 2012
Expected CE-marking and launch in Europe in 2012 Holzgerlingen, Germany, February 16, 2012 -- Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagn [...]
Achmea en LSP lanceren het LSP-Health Economics Fund voor innovatie in de zorg Friday, February 10th, 2012
Zeist / Amsterdam, 10 februari 2012 – Verzekeraar Achmea en investeringsmaatschappij Life Sciences Partners (LSP) hebben de voorbereidingen afgerond voor de inrichting van een investeringsfonds voor innovaties in de zo [...]
arGEN-X advances a third therapeutic antibody program into preclinical development Wednesday, February 8th, 2012
ARGX-111 IS AN ANTI-C-MET ANTIBODY WITH BROAD APPLICABILITY IN CANCER Rotterdam, the Netherlands and Ghent, Belgium February 8, 2012–arGEN-X, a biopharmaceutical company focused on the discovery and development of h [...]
Hybrigenics revenues grew 45% to EUR 6.6 million in 2011 Monday, January 30th, 2012
Hybrigenics Services contributed for EUR 4.1 million, a 17% growth In 2011, Hybrigenics Pharma has signed a major drug discovery contract and expanded the clinical development scope of inecalcitol Paris, 30 January [...]
Prosensa Raises €23 Million in New Equity Financing Led by New Enterprise Associates Wednesday, January 25th, 2012
Leiden, The Netherlands, 25 January 2012 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet needs, announced today that it has raised €23 million [...]
Pronota announces EUR 3.7 million Series C financing; management and board changes Friday, January 20th, 2012
Ghent, Belgium; Pronota NV today announced the close of a Series C financing, raising EUR 3.7 million from existing investors; LSP, Gimv, Biotech Fund Flanders, KBC Private Equity, Johnson & Johnson Development Corporati [...]
Hybrigenics targets chronic lymphocytic leukemia (CLL) as the third therapeutic indication for its oral inecalcitol Thursday, January 19th, 2012
Hybrigenics filed a clinical trial application to test inecalcitol, a vitamin D receptor agonist, in CLL patients Hybrigenics started a collaboration with Necker Institute, Paris,on vitamin D receptor and CLL Paris [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund